10-Q: Cannabis Bioscience Faces Steep Revenue Drop, Going Concern Doubt

Cannabis Bioscience International Holdings, Inc. reported a significant revenue decline and increased net loss, raising substantial doubt about its ability to continue as a going concern.

Summary

• Revenues for the quarter ended August 31, 2025, plummeted to $24,200 from $178,887 in the prior year, primarily due to a $149,047 decrease in clinical trial contracts.
• Net loss for the quarter increased to $82,645, compared to a net loss of $76,305 for the same period last year.
• Cash and cash equivalents decreased significantly to $223 as of August 31, 2025, from $12,952 on May 31, 2025, with current cash at $128 as of October 22, 2025.
• Working capital deficit worsened to $996,728 at August 31, 2025, from $916,878 at May 31, 2025.
• Accumulated deficit grew to $5,965,546 as of August 31, 2025.
• Net cash used in operations increased to $103,712 for the quarter, up from $30,413 in the prior year period.
• Multiple short-term loans and a related-party loan are in default, and payments under other agreements are in arrears.
• Disclosure controls and procedures were deemed not effective as of August 31, 2025.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a severe revenue collapse, increased net losses, critically low cash reserves, a worsening working capital deficit, and explicit disclosure of substantial doubt about the company's ability to continue as a going concern. The ineffective disclosure controls further compound the negative outlook.

Positives

• Total operating expenses decreased to $90,841 from $268,129 in the prior year, largely due to a $100,000 reduction in non-cash share-based compensation.
• Operating loss improved (less negative) to $74,784 from $97,604 in the prior year period.
• A non-cash gain of $29,322 was recorded from the change in value of derivative liabilities during the quarter.

Negatives

• Revenue declined by 86.5% year-over-year, primarily driven by a significant reduction in clinical trial contracts.
• Net loss increased, indicating worsening profitability despite reduced operating expenses.
• Cash and cash equivalents are critically low at $223, further deteriorating to $128 as of the report date.
• The working capital deficit expanded, highlighting severe liquidity issues.
• An accumulated deficit of $5,965,546 indicates a history of unprofitability.
• Cash used in operating activities more than tripled, signaling an unsustainable cash burn rate.
• Several non-convertible loans and a related-party loan are in default, and payments on other loans are in arrears.
• Interest expense increased significantly to $17,368 from $2,339 in the prior year period.
• A substantial portion of gross revenue (95% for the current quarter) is concentrated among two customers, posing a significant risk.

Risks

• Substantial doubt exists about the ability to continue as a going concern due to recurring losses, negative working capital, and negative cash flows from operations.
• High dependence on obtaining additional debt or equity financing, with no assurance of success on satisfactory terms.
• Risk of curtailing or ceasing operations if adequate capital cannot be obtained.
• Significant revenue concentration with two customers (95% of gross revenue) creates vulnerability to loss of business from either customer.
• Ineffective disclosure controls and procedures as of August 31, 2025, indicate weaknesses in financial reporting oversight.
• Multiple loans are in default, exposing the company to potential legal action and further financial strain.
• The company operates in the medical cannabis industry, which is subject to evolving regulatory landscapes and potential legal challenges.

Future Outlook

The company's ability to continue as a going concern depends on the successful execution of its operating plan, which includes expanding operations, increasing sales of existing services, introducing new services, and raising either debt or equity financing. There is no assurance that additional capital can be obtained on satisfactory terms or at all, and the company may be required to curtail or cease its operations.

Management Comments

• "The Company needs substantial additional capital to fund its business and repay its debts."
• "No assurance can be given that any additional capital can be obtained or, if obtained, will be adequate to meet its needs, and the Company may need to take measures to remain a going concern."

Industry Context

The company operates in the medical cannabis and clinical trials sectors, both of which can be capital-intensive and subject to significant regulatory and market risks. The substantial decline in clinical trial revenue suggests a failure to secure new contracts or retain existing ones, which could be indicative of competitive pressures or internal operational challenges rather than broad industry contraction. The cannabis industry, in particular, often faces challenges in accessing traditional financing, which may exacerbate the company's stated need for capital.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or industry benchmarks for direct assessment.
• A revenue decline of over 86% year-over-year is significantly worse than typical industry performance, even in volatile sectors.
• A working capital deficit approaching $1 million and critically low cash balances are indicative of severe financial distress, far below healthy industry liquidity standards.
• Multiple loan defaults and reliance on related-party financing suggest an inability to secure capital from conventional lenders, which is a red flag compared to well-capitalized industry peers.

Corporate Governance

Related Party Transactions

• Lease of office space from one of the company's officers, with monthly payments of $3,333.
• The Headway Loan was guaranteed by a related party.
• An undocumented $15,000 loan from a related party (August 2022) is believed to be in default.
• The Jones Note, a promissory note for $340,855, was made in favor of John Jones and Barbara Kamienski (related parties), replacing previous notes.
• Cash advances totaling $93,569 were received from related parties for working capital during the quarter ended August 31, 2025.
• Related party liabilities owed to certain shareholders totaled $717,043 as of August 31, 2025.
• Related party receivables owed by certain shareholders totaled $9,155 as of August 31, 2025.
• Issuance of 1,000 shares of Series B Preferred Stock to a related party as compensation for services in raising capital.
• Authorization for issuance of 125,000,000 shares of Common Stock to a related party (Treasurer) and another 125,000,000 shares to a related party (Secretary) as compensation for services, contingent on their continued service.

Stakeholder Impact

• Shareholders face significant risk of capital loss due to the company's going concern issues, severe financial deterioration, and potential for further dilution if new equity financing is pursued.
• Creditors, particularly those with defaulted loans, face uncertainty regarding repayment and potential for legal action.
• Employees may face job insecurity given the company's financial distress and the possibility of operational curtailment.
• Customers, especially the two highly concentrated customers, may face risks related to service continuity if the company's financial situation does not improve.
• Suppliers may experience delays or non-payment for services or goods provided.

Next Steps

• Expand operations and increase sales of existing services.
• Introduce new services.
• Raise either debt or equity financing to fund operations and repay debts.

Key Dates

Recommendation

The company exhibits severe financial distress, including an 86.5% year-over-year revenue decline, increased net losses, critically low cash reserves ($223), and a worsening working capital deficit. Management has explicitly raised substantial doubt about the company's ability to continue as a going concern, citing a need for significant capital with no assurance of obtaining it. Multiple loans are in default, and disclosure controls are ineffective. These factors collectively indicate an extremely high-risk investment with a strong likelihood of further value erosion or business failure.

Keywords

Cannabis, Bioscience, CBD, Clinical Trials, Pharmacology University, SEC 10-Q, Financials, Going Concern, Debt Default, Related Party Transactions, Revenue Decline, Liquidity Crisis